HISCOX LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,142 GBX | -.--% |
|
-2.06% | +8.35% |
| May. 08 | UBS raises Centrica to 'buy' from 'neutral | AN |
| May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
| Sales 2024 * | 3.89B 4.96B | Sales 2025 * | 4.27B 5.44B | Capitalization | 3.91B 4.98B |
|---|---|---|---|---|---|
| Net income 2024 * | 466M 594M | Net income 2025 * | 500M 637M | EV / Sales 2024 * | 1.14 x |
| Net Debt 2024 * | 513M 654M | Net Debt 2025 * | 513M 654M | EV / Sales 2025 * | 1.04 x |
| P/E ratio 2024 * |
8.37
x | P/E ratio 2025 * |
7.69
x | Employees | 3,000 |
| Yield 2024 * |
2.82% | Yield 2025 * |
3.13% | Free-Float | 97.46% |
More Fundamentals
* Assessed data
More news
Latest transcript on Hiscox Ltd
More press releases
| 1 week | -2.06% | ||
| 1 month | -7.15% | ||
| 3 months | +0.79% | ||
| 6 months | +12.40% | ||
| Current year | +8.35% |
1 week
1 129.00
1 176.00
1 month
1 114.001 277.85
Current year
998.001 277.85
1 year
926.041 277.85
3 years
769.401 277.85
5 years
635.401 795.00
10 years
635.401 795.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hamayou Hussain
CEO | Chief Executive Officer | 51 | 16-04-21 |
Paul Cooper
DFI | Director of Finance/CFO | 52 | 22-05-11 |
Stéphane Flaquet
COO | Chief Operating Officer | - | 10-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 17-11-15 | |
Jonathan Bloomer
CHM | Chairman | 70 | 23-05-31 |
Anne MacDonald
BRD | Director/Board Member | 68 | 15-05-19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.06% | 746 M€ | -.--% | - | |
| 0.02% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 1,142 | -.--% | 2,764,851 |
| 24-05-30 | 1,142 | +0.35% | 1,586,806 |
| 24-05-29 | 1,138 | -0.18% | 652,966 |
| 24-05-28 | 1,140 | -2.23% | 888,938 |
| 24-05-24 | 1,166 | +1.30% | 601,640 |
Delayed Quote London S.E., May 31, 2024 at 11:35 am EDT
More quotes
Hiscox Ltd is a Bermuda-based diversified international insurance company. The Company is a holding company for subsidiaries involved in the business of insurance and reinsurance in Bermuda, the United States, the United Kingdom, Guernsey, Europe and Asia. The Companyâs segments include Hiscox Retail, Hiscox London Market, Hiscox Re & ILS and Corporate Centre. The Hiscox Retail segment includes results of the Companyâs retail business divisions in the United Kingdom, Europe, United States and Asia. The Hiscox UK and Hiscox Europe divisions underwrite personal and commercial lines of business. The Hiscox USA division comprises commercial, property and specialty businesses. The Hiscox London Market consists of the internationally traded insurance business, including lines in property, marine and energy, casualty and other specialty insurance lines. The Hiscox Re & ILS segment is the reinsurance division of the Company, combining the underwriting platforms in Bermuda and London.
Calendar
2024-07-29
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
11.42
GBP
Average target price
12.93
GBP
Spread / Average Target
+13.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.35% | 4.98B | |
| +53.84% | 67.71B | |
| +16.34% | 52.31B | |
| +13.23% | 49.39B | |
| +19.67% | 44.21B | |
| +38.21% | 38.39B | |
| +77.48% | 33.19B | |
| +11.86% | 29.8B | |
| +25.50% | 25.35B | |
| -0.43% | 21.46B |
- Stock Market
- Equities
- HSX Stock
